Our study demonstrated an impact of ACE2 on IFN signaling components in tumor cell lines and patients’ samples, which is linked to an upregulation of HLA class I, but also of PD-L1, suggesting that cancer patients with COVID-19 might have an increased response to checkpoint inhibitor treatment, such as nivolumab or durvalumab. This evidence concerns the gene CD274 and COVID-19.